Dopastin
| |
| Nazivi | |
|---|---|
| Sistemski IUPAC naziv
(2E)-N(2S)-2-[Hidroksi(nitrozo)amino]-3-metilbutil2-butenamid | |
| Identifikacija | |
3D model (Jmol)
|
|
| ChemSpider | |
| |
| Svojstva | |
| C9H17N3O3 | |
| Molarna masa | 215,25 g·mol−1 |
| Tačka topljenja | 116-119 °C[3] |
| Kiselost(pKa) | 5,1[3] |
Ukoliko nije drugačije napomenuto, podaci se odnose nastandardno stanjematerijala (na 25 °C [77 °F], 100 kPa). | |
| Reference infokutije | |
Dopastinje hemijsko jedinjenje koje formira bakterijaPseudomonasNo. BAC-125.[4]Ono je prvi put izolovano i okarakterisano1972.Dopastin deluje kaoinhibitorenzimadopaminska β-hidroksilaza.[5]
Dopastin se može sintetički pripremiti izL-valinola.[6]
Reference
[уреди|уреди извор]- ^Li Q, Cheng T, Wang Y, Bryant SH (2010).„PubChem as a public resource for drug discovery.”.Drug Discov Today.15(23-24): 1052—7.PMID20970519.doi:10.1016/j.drudis.2010.10.003.
- ^Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry.4:217—241.doi:10.1016/S1574-1400(08)00012-1.
- ^абThe Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals(11th изд.). Merck Publishing. 1989.ISBN091191028X.,pages+3417 </noinclude>
- ^Iimura, H; Takeuchi, T; Kondo, S; Matsuzaki, M; Umezawa, H (1972). „Dopastin, an inhibitor of dopamine -hydroxylase”.The Journal of antibiotics.25(8): 497—500.PMID4648494.
- ^H. Iinuma; M. Matsuzaki; T. Nagatsu; T. Takeuchi; H. Umezawa (1974). „Biochemical and biological studies on dopastin, an inhibitor of dopamine β-hydroxylase”.Agric. Biol. Chem.38(11): 2107—2111.doi:10.1271/bbb1961.38.2107.
- ^Ohno, M.; Iinuma, H.; Yagisawa, N.; Shibahara, S.; Suhara, Y.; Kondo, S.; Maeda, K.; Umezawa, H. (1973). „Synthesis of dopastin, a dopamine?-hydroxylase inhibitor of microbial origin”.Journal of the Chemical Society, Chemical Communications(4): 147.doi:10.1039/C39730000147.
